Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?
Wu
Wenchen Kenneth
WK
Duh
Mei Sheng
MS
Lefebvre
Patrick
P
D000740:Anemia / Q000139:chemically induced* / Q000188:drug therapy*; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use*; D006801:Humans
D000998:Antiviral Agents; D004921:Erythropoietin